JP2016527900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527900A5 JP2016527900A5 JP2016534613A JP2016534613A JP2016527900A5 JP 2016527900 A5 JP2016527900 A5 JP 2016527900A5 JP 2016534613 A JP2016534613 A JP 2016534613A JP 2016534613 A JP2016534613 A JP 2016534613A JP 2016527900 A5 JP2016527900 A5 JP 2016527900A5
- Authority
- JP
- Japan
- Prior art keywords
- primer
- cmet
- level
- gene
- amplicon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 39
- 108091093088 Amplicon Proteins 0.000 claims 28
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 108091092584 GDNA Proteins 0.000 claims 16
- 210000000349 chromosome Anatomy 0.000 claims 10
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 10
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 10
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 10
- 230000004544 DNA amplification Effects 0.000 claims 8
- 108020004999 messenger RNA Proteins 0.000 claims 8
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 claims 6
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 claims 6
- 230000003321 amplification Effects 0.000 claims 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims 6
- 208000031715 Autosomal recessive spastic paraplegia type 21 Diseases 0.000 claims 4
- 101000825177 Homo sapiens Maspardin Proteins 0.000 claims 4
- 102100022280 Maspardin Human genes 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 208000000540 mast syndrome Diseases 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000011541 reaction mixture Substances 0.000 claims 4
- 238000012408 PCR amplification Methods 0.000 claims 3
- 238000000137 annealing Methods 0.000 claims 3
- 238000000926 separation method Methods 0.000 claims 3
- 101150039808 Egfr gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108700021358 erbB-1 Genes Proteins 0.000 claims 2
- 102220197908 rs121913244 Human genes 0.000 claims 2
- 102220197954 rs121913245 Human genes 0.000 claims 2
- 102220004853 rs121913246 Human genes 0.000 claims 2
- 102220004849 rs121913668 Human genes 0.000 claims 2
- 102220004850 rs121913669 Human genes 0.000 claims 2
- 102220004851 rs121913670 Human genes 0.000 claims 2
- 102220004852 rs121913671 Human genes 0.000 claims 2
- 102220004854 rs121913673 Human genes 0.000 claims 2
- 102220004857 rs121913677 Human genes 0.000 claims 2
- 102200046768 rs3744825 Human genes 0.000 claims 2
- 102220105192 rs771328219 Human genes 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 208000011932 ovarian sarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361865755P | 2013-08-14 | 2013-08-14 | |
| US61/865,755 | 2013-08-14 | ||
| PCT/US2014/050076 WO2015023503A2 (en) | 2013-08-14 | 2014-08-07 | Compositions and methods for multimodal analysis of cmet nucleic acids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016527900A JP2016527900A (ja) | 2016-09-15 |
| JP2016527900A5 true JP2016527900A5 (enExample) | 2017-06-22 |
Family
ID=51358135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016534613A Pending JP2016527900A (ja) | 2013-08-14 | 2014-08-07 | ｃＭＥＴ核酸のマルチモード解析のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160130660A1 (enExample) |
| EP (1) | EP3033434A2 (enExample) |
| JP (1) | JP2016527900A (enExample) |
| KR (1) | KR20160106040A (enExample) |
| CN (1) | CN105745335A (enExample) |
| BR (1) | BR112016003057A2 (enExample) |
| CA (1) | CA2917924A1 (enExample) |
| SG (1) | SG11201600754PA (enExample) |
| WO (1) | WO2015023503A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230169197A (ko) | 2014-11-14 | 2023-12-15 | 보이저 테라퓨틱스, 인크. | 근위축성 측삭 경화증(als)을 치료하는 조성물 및 방법 |
| WO2018025856A1 (ja) * | 2016-08-02 | 2018-02-08 | 学校法人武庫川学院 | 簡便な遺伝子検査法およびコピー数計測法ならびにその支援技術 |
| CA3061652A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| AU2018352236B2 (en) | 2017-10-16 | 2025-04-10 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| CN108893536B (zh) * | 2018-07-13 | 2022-02-15 | 江苏省人民医院（南京医科大学第一附属医院） | 一种从人外周血CTC中检测c-MET基因拷贝数变异的方法和试剂盒 |
| EP3837383A1 (en) * | 2018-08-16 | 2021-06-23 | Life Technologies Corporation | Reagents, mixtures, kits and methods for amplification of nucleic acids |
| KR20210107492A (ko) * | 2020-02-24 | 2021-09-01 | (재)록원바이오융합연구재단 | 복제수 변이 검출용 표준화 유전자의 선별 방법 및 상기 방법에 의해서 선별된 c-Met 복제수 변이 검출용 조성물 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US7445893B2 (en) | 2002-04-12 | 2008-11-04 | Primera Biosystems, Inc. | Sampling method for amplification reaction analysis |
| US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| US8321140B2 (en) | 2007-11-07 | 2012-11-27 | Primeradx, Inc. | Quantification of nucleic acid molecules using multiplex PCR |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| PA8849001A1 (es) * | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| CN102439171B (zh) * | 2008-12-22 | 2017-07-14 | 犹他大学研究基金会 | 单色多重定量pcr |
| KR20140002711A (ko) * | 2010-12-23 | 2014-01-08 | 네스텍 소시에테아노님 | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 |
| EP2681552A2 (en) * | 2011-03-02 | 2014-01-08 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
-
2014
- 2014-08-07 EP EP14752755.0A patent/EP3033434A2/en not_active Withdrawn
- 2014-08-07 CN CN201480056221.9A patent/CN105745335A/zh active Pending
- 2014-08-07 KR KR1020167006476A patent/KR20160106040A/ko not_active Withdrawn
- 2014-08-07 JP JP2016534613A patent/JP2016527900A/ja active Pending
- 2014-08-07 SG SG11201600754PA patent/SG11201600754PA/en unknown
- 2014-08-07 BR BR112016003057A patent/BR112016003057A2/pt active Search and Examination
- 2014-08-07 US US14/897,323 patent/US20160130660A1/en not_active Abandoned
- 2014-08-07 CA CA2917924A patent/CA2917924A1/en not_active Abandoned
- 2014-08-07 WO PCT/US2014/050076 patent/WO2015023503A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016527900A5 (enExample) | ||
| Kim et al. | Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing | |
| Wee et al. | Simple, sensitive and accurate multiplex detection of clinically important melanoma DNA mutations in circulating tumour DNA with SERS nanotags | |
| Kawakami et al. | XISTunmethylated DNA fragments in male-derived plasma as a tumour marker for testicular cancer | |
| Pisanic et al. | DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies | |
| FI3122897T3 (fi) | Kohdenukleiinihapposekvenssien detektointi erilaisia detektointilämpötiloja käyttäen | |
| JP2015156872A5 (enExample) | ||
| Xiang et al. | Isothermal detection of multiple point mutations by a surface plasmon resonance biosensor with Au nanoparticles enhanced surface-anchored rolling circle amplification | |
| JP2017501685A5 (enExample) | ||
| JP2013532494A5 (enExample) | ||
| JP2012526563A5 (enExample) | ||
| Ludwig et al. | Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAs | |
| BR112016003057A2 (pt) | composições e métodos para análise multimodal de ácidos nucleicos cmet | |
| JP2014030431A5 (enExample) | ||
| JP2024012522A5 (enExample) | ||
| JP2013090622A (ja) | 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット | |
| JP2014530011A5 (enExample) | ||
| Liu et al. | Potential clinical significance of plasma-based KRAS mutation analysis using the COLD-PCR/TaqMan®-MGB probe genotyping method | |
| Combaret et al. | Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA | |
| Sebuyoya et al. | Integrating isothermal amplification techniques and LNA-based AI-assisted electrochemical bioassay for analysis of KRAS G12V point mutation | |
| Potocnik et al. | Short prokaryotic Argonaute system repurposed as a nucleic acid detection tool | |
| JP2017501733A5 (enExample) | ||
| Wang et al. | SNP–STR polymorphism: A sensitive compound marker for forensic genetic applications | |
| Mauger et al. | Enrichment of methylated molecules using enhanced-ice-co-amplification at lower denaturation temperature-PCR (E-ice-COLD-PCR) for the sensitive detection of disease-related hypermethylation | |
| Wei et al. | Detection of BRAFV600E mutation of thyroid cancer in circulating tumor DNA by an electrochemical-enrichment assisted ARMS-qPCR assay |